Total
0
Shares
Newly appointed consultant, Dr Jeremy Tannenbaum. Source: Dr Jeremy Tannenbaum/LinkedIn
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Emyria (EMD) appoints Dr Jeremy Tannenbaum as a consultant to support the company’s psychedelic-assisted therapy programs
  • The doctor has been contracted to advise on Emyria’s MDMA-assisted psychotherapy trial for PTSD, its MDMA-analogue drug discovery and screening pipeline, and other research and development activities
  • Emyria says its goal is to develop a leading, scalable, evidence-based model for MDMA-assisted psychotherapy delivery
  • Emyria ended the day up 2.13 per cent, trading at 24 cents

Emyria (EMD) has appointed a consultant to support its psychedelic-assisted therapy programs.

Dr Jeremy Tannenbaum has been contracted to assist with the development of the company’s MDMA-analogue development.

The doctor has been contracted to advise on Emyria’s MDMA-assisted psychotherapy trial for post-traumatic stress disorder (PTSD), its MDMA-analogue drug discovery and screening pipeline and its research and development of novel approaches for people with complex pain conditions.

The company said there is a strong body of evidence that shows substances such as ketamine, psilocybin, and MDMA, when used in a controlled environment and supported by psychotherapy, offer a promising new approach to treating major mental illnesses that are resistant to first-line treatments.

Following training, Dr Tannenbaum will be one of only a small number of specialist medical practitioners in Australia to hold dual qualifications in both psychiatry and pain medicine.      

Emyria’s Managing Director, Dr. Michael Winlo, said the company was delighted to welcome the doctor to its ‘world-class’ clinical advisory.

“We believe Dr. Tannenbaum’s unique and diverse training in psychiatry and pain medicine can greatly advance Emyria’s MDMA-assisted psychotherapy trials for PTSD, our MDMA-analogue discovery and screening program, and also support Emyria to evaluate the use of cannabinoid and other novel therapeutic approaches to address the biopsychosocial aspects of complex pain management.”

Emyria said its goal is to develop a leading, scalable, evidence-based model for MDMA-assisted psychotherapy delivery.

Emyria was up 2.13 per cent, trading at 24 cents at market close.

EMD by the numbers
More From The Market Herald
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson

" Anteris Technologies (ASX:AVR) eyes $5m for DurAVR

Anteris Technologies (AVR) has placed 625,000 new ordinary shares to Melbourne-based global investor L1 Capital to raise $5 million.
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test

Atomo Diagnostics (AT1) can now supply its HIV self-test to a greater variety of organisations and begin advertising thanks to recent changes made
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Starpharma (SPL) has penned an initial deal to distribute and supply its VIRALEZE antiviral nasal spray in Vietnam.
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.